• STAT+: CRISPR patent fight redux? A new battle is brewing among biotechs over next-gen gene-editing tools

    24 days ago - By STAT

    Genome editing summits are generally friendly, nerdy affairs, but for a moment at a Lisbon hotel last June, the conversation at the FASEB genome engineering conference grew tense.
    Tessera Therapeutics chief scientist Michael Holmes had just finished presenting a much-anticipated peek at a technology the company had previously said could “ revolutionize genetic medicine ” and “cure nearly any genetic disease.” It was a rare moment: Tessera had raised around $600 million and passed a $1 billion valuation, but published little in academic medical journals. Continue to STAT+ to read the full...
    Read more ...